It is the world’s most cultivated, trafficked, and used illicit drug, and because the momentum for group action grows reception and abroad, marijuana is attracting vital attention from investors, makers, and researchers. Despite the fact that the plant is illegal under federal law as a Schedule I drug, the US legal marijuana industry. The USA It was estimated at $ 10.4 billion in 2018 with 250,000 jobs dedicated to planting management, according to New Frontier Data. A total of 33 states have legalized marijuana for medical use, 10 of which allow adults to legally use the drug for recreational use. And that number may continue to rise, as more people embrace the idea of legalizing marijuana in the United States. This article looks at some of the uses of marijuana, as well as the generic drug market.
Change of attitudes towards the pot
Remember “Reefer Madness”, the 1930s movie that was produced to teach parents and their children about the threat of marijuana? Originally, the film was intended to educate the public but has now become a cult classic and satire.
Just as the attitude about the movie has changed, so too have people’s feelings about marijuana. This is especially true as we learn more about the drug and the apparent benefits of using it for medical purposes. Once considered an illicit substance, it is still considered a controlled drug according to federal government guidelines. But the stigma is being removed at an impressive rate, and it appears that marijuana is on its way to the mainstream.
According to a Pew Research survey, 62% of Americans believe that marijuana use should be legalized. This is double what it was in 2000—31%, and five times more than in 1969—12%. A New York University study revealed that the percentage of adults ages 50 to 64 who reported that marijuana use doubled in the past decade to 9% and that use among adults age 65 and older increased sevenfold during the same period to almost 3%. The US Marijuana Industry USA It will generate $ 17.5 billion in tax revenue by 2030, according to Cowen analyst Vivien Azer.
With Jeff Sessions gone and Democrats in control of the House, a significant pot reform seems possible this year. The politician noted that 296 members of Congress (68%) represent the 33 states with at least medical marijuana, which means there are enough votes to pass long-awaited bills. There are already several bills in the new Congress related to marijuana.
Marijuana firms raised $ thirteen.8 billion in funds in 2018, consistent with cannabis business analysis firm Viridian Capital Advisors. This was fourfold the quantity raised in 2017. We can expect this trend to continue, but important for the US industry. The USA It is also banking reform. Today, big banks fear the money laundering charges they may face if they work with these businesses. In addition to the difficulty in obtaining capital, this implies enormous risks and inconveniences for companies that operate in cash. The Bankers’ Association of America has been pushing for a lot of legal clarity and shutting the gap between federal and state law, and that we might see however banks heat up to cannabis if bills just like the SAFE Banking Act are passed.
More states can also legalize marijuana, including New York, New Jersey, Illinois, and Connecticut.
United States Attorney General William Barr announced that he will not go after marijuana companies that operate in states where the plant is legal. He also said the current discrepancy between state and federal law is “unsustainable” and needs to be redressed. Supports a federal law that prohibits marijuana everywhere.
Several candidates for the 2020 presidential election have expressed their support for the legalization of cannabis. Here are some of the important names and how they feel:
- Former Vice President Joe Biden wants marijuana to be decriminalized and the criminal records of those convicted of drug possession removed.
- South Bend Mayor Pete Buttigieg wants all drugs to be decriminalized, calling for drug penalties to be reduced and drug possession convictions to be removed entirely.
- Senator Kamala Harris is one of the sponsors of a bill called the Marijuana Justice Act along with Sens. Cory Booker and Elizabeth. As part of their platform, the three senators support the revocation of convictions for those caught with marijuana, and each calls for a path to decriminalization and legalization.
Marijuana has been used as a medicine in different cultures for thousands of years. The federal law that prohibits it in the US Marijuana Tax Act was passed in 1937. There is now increasing acceptance of the plant as a legitimate option for patients suffering from medical problems like chronic pain or seizures in today’s the United States.
This is mainly due to cannabidiol, or CBD, a natural compound found in cannabis plants that is not psychoactive. This means that it does not elevate the consumer. CBD is sold as an ingredient in oils, oral sprays, creams, pills, or groceries such as jelly beans and lollipops. Providers claim that CBD can ease pain, combat anxiety and depression. It has even been linked to helping people living with cancer.
It is true that CBD is having its moment. The term CBD jelly beans were the third most searched Google food term in the US. The USA In 2018. Big companies like Corona’s owner, Constellation Brands (STZ.B), and cigarette maker Marlboro, Altria Group (MO), have bought multi-million dollar stakes in marijuana companies. But forecasts for the CBD market argue that this It is not just a temporary wellness fad.
New Frontier Data estimates that the hemp-derived CBD market will grow from a $ 390 million market in 2018 to a $ 1.3 billion market, or 3.3x, by 2022. Brightfield Group says the hemp CBD market it can reach up to $ 22 billion by 2022. Defending his lofty prediction, Brightfield decision-maker Bethany Gomez said: “We are a team of extremely conservative analysts and that we don’t take this gently. I honestly believe these are conservative numbers. We don’t have pink lenses in terms of the strange and challenging regulatory framework that surrounds this industry, there will always be two steps forward, one step back. There will surely be some troublesome regulations and obstacles along the way. But there is too much momentum, too much demand. and also a lot of potentials for this industry not to explode. ”
FDA and CBD: Softening Posture?
Under the current rules of the US Food and Drug Administration. USA (FDA), all drugs that contain CBD, a Annex I substance, require agency approval. In June 2018, the agency also approved CBD, a drug derived from marijuana for the first time. GW Pharmaceuticals Epidiolex (GWPH) was placed on the least restrictive Schedule V of the Controlled Substances Act by the US Drug Control Administration. USA (DEA), which means it has a low potential for abuse.
According to federal regulations, it is also illegal to market CBD-containing food products or dietary supplements, but the FDA has indicated that it may change in the future. In a December 2018 press release, he said: “Although the introduction of such products into interstate commerce is generally prohibited, the FDA has the authority to issue a regulation that allows the use of a pharmaceutical ingredient in a food or dietary supplement.”, said. “We are taking new steps to assess whether we should continue that process.” The statement was released after the Farm Bill that legalized regulated production of hemp, another source of CBD, was passed.
This is great news for many companies that bet on the complex and face its murky legal situation. But can investors expect all of the CBD to be placed on Schedule V or not scheduled soon? Not quite. It is not easy that the CBD is not fully programmed due to the international treaties that the United States has signed. And while Epidiolex qualifies for Annex V, only other FDA-approved marijuana-derived drugs with low THC levels can hope to join there.
Since the explosion of marijuana products is almost certain, experts are now wondering what the industry would be like. Will giant companies return to dominate it and flood the market with an inexpensive and generic product? Ryan Stoa, professor of law at Concordia University and author of “Craft Weed: Family Farming and the Future of the Marijuana Industry,” told The Verge that this will be difficult due to the variety of strains available. Another factor discussed was the interest of the consumer base in locally made or locally made artisan products.
“In terms of the dimensions of the regulator, states have a task to play,” the same. “States like American state are already seen swing a cap or limit on the dimensions of marijuana farms, primarily oral communication, ‘If we’re planning to decriminalize this trade, we want to distribute the benefits to as many people as possible.'” Other states are able to replicate that model. ”
Technology is also shaping the industry. Weed delivery company Eaze has raised $ 37 million and is reportedly valued at $ 300 million. It recently announced that it is creating a platform to ship CBD products to 41 states. On-demand marijuana and cannabis delivery service Dutchie raised $ three million in 2018 from the working capital corporations of rapper Snoop Dogg and basketeer Kevin Will Durant, among others. Expect to hear words like machine learning, automation, and blockchain that are most frequently used in relation to marijuana. Trac promises to solve the banking problems of the industry. CannaCloud is the Keurig for the herb. Bloom Automation is building robots to trim and method cannabis.
Compete risk-free with $ 100,000 in virtual cash
Test your trading skills with our free stock simulator. Compete with thousands of Investopedia merchants and trade to the top! Submit trades during virtual surroundings before you begin risking your own cash. Practice trading strategies so that when you’re ready to enter the real market, you have the practice you need.